PROBLEM TO BE SOLVED: To provide a new therapeutic or prophylactic agent for disorders such as: mood disorder, anxiety disorder, schizophrenia, Alzheimers disease, Parkinsons disease, Huntington chorea, eating disorder, hypertension, digestive disorder, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immune-related disorder, alopecia, etc.SOLUTION: A therapeutic or prophylactic agent for disorders such as: mood disorder, anxiety disorder, schizophrenia, Alzheimers disease, Parkinsons disease, Huntington chorea, eating disorder, hypertension, digestive disorder, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immune-related disorder, alopecia, etc., contains as an effective ingredient, 1,2,4-triazolone derivative expressed by general formula (1A) or pharmaceutically permissive salts thereof having arginine-vasopressin 1b receptor antagonistic action.COPYRIGHT: (C)2014,JPO&INPIT【課題】新規な気分障害、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、脱毛症等の疾患の治療又は予防剤を提供すること。【解決手段】アルギニン-バソプレッシン1b受容体拮抗作用を有する一般式(1A)で表される1,2,4-トリアゾロン誘導体、又はその医薬上許容される塩を有効成分として含有する気分障害、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、脱毛症等の疾患の治療又は予防剤。【選択図】なし
